Imaging the Vulnerable Plaque

David A. Dowe, MD
Atlantic Medical Imaging
Why is this so important?
The Acute Situation

Majority of MIs are associated with non-flow limiting, unstable lesions

- Stenosis Prior to MI
  - > 70%
  - 50-70%
  - < 50%

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10</td>
<td>20</td>
<td>30</td>
<td>60</td>
<td>14%</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>30</td>
<td>40</td>
<td>80</td>
<td>18%</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>40</td>
<td>50</td>
<td>100</td>
<td>68%</td>
</tr>
</tbody>
</table>

Coronary disease - Important

- Diagnosis of cardiovascular disease cost $148 billion in 2006
- 5 million patients visit emergency department with chest pain/year.
- Commonest cause for medicolegal litigation within the emergency department

AHA. Heart & stroke statistics-2006 update Dallas 2006
Traditional CAD Risk Factors

- Traditional CAD risk factors are incomplete in predicting CAD events.
- 50% of patients with an acute MI have normal cholesterol profiles.
- Sudden death is the FIRST (and last) sign of CAD in 150,000 people/year.
Traditional Clinical Risk Assessment Tools Do Not Accurately Predict Coronary Atherosclerotic Plaque Burden: A CT Angiography Study

Traditional Clinical Risk Assessment Tools Do Not Accurately Predict Coronary Atherosclerotic Plaque Burden: A CT Angiography Study

- 26% of patients had no plaque but were already on statins for life.
- 21% had no need for statins yet had plaque at as high or higher than the median for patients with known CAD.
- 20% of plaque is calcified and 18% of patients with plaque have no calcium.
Lowering Cholesterol with Statin Medication

- Statins reduce blood cholesterol, risk of MI by 33%.
- 25-50 million in US could benefit.
- 4-5 million on statin therapy in US (costs $2000/year/patient)
Atherosclerosis: Traditional vs contemporary model

Traditional

Contemporary

Thanks to Carl Roobottom, MD
Pathophysiology of coronary atheroma

- Starry classification 1995
Pathophysiology of coronary atheroma

- Fatty streaks deposited in 20’s
Pathophysiology of coronary atheroma

- Further deposition results in vessel expansion = positive remodelling
Pathophysiology of coronary atheroma

- Deposition within wall = inflammation
Pathophysiology of coronary atheroma

- Interspersed with episodes of plaque rupture
Pathophysiology of coronary atheroma

- Repeated plaque rupture and inflammation causes fibrosis +/- luminal narrowing
Pathophysiology of coronary atheroma

- Stabilized plaque is formed in 10-20 years
Summary Points:

- Atheroma is a disease of the vessel wall
- The process of positive remodelling means luminal diameter is maintained for a long period of its natural history and are therefore undetectable by stress tests and caths.
- Coronary stenosis (and coronary calcium) are end stage consequences of repeated inflammation
How do we currently diagnose coronary disease?
By looking at the lumen!
Remodeling in an angiographically “normal” artery

IVUS is the gold standard

- Invasive
- Expensive
- Only assesses proximal vessels
- Carries risk
- Changes groin management
- THEREFORE NOT WIDELY APPLICABLE
The Incremental Value of Coronary Catheterization

- With the exception of left main stem disease and severe 3 vessel disease intervention has no prognostic benefit.
- Intervention is for symptomatic disease providing their symptoms are related to CAD.
- It does not stop patients from dying!
- Why?
Cath does not detect the lesions that cause 86% of ACS

thrombosis $\Rightarrow$ sudden death, MI, unstable angina
“It’s the doughnut, not the hole.”
Rupture in bulky, remodeled atheroma: Angiographic findings

The Cleveland Clinic Intravascular Ultrasound Research Laboratory.
Rupture in bulky, remodeled atheroma: IVUS findings

The Cleveland Clinic Intravascular Ultrasound Research Laboratory.
Plaque rupture proximal to a severely stenotic lesion

The Cleveland Clinic Intravascular Ultrasound Research Laboratory.
Clinical Reality

- **Non invasive tests look for end organ ischemia or damage, not vulnerable plaque**
- **Intravascular ultrasound is expensive, invasive and not without risk**
- **Angiography is the best test we have got!**
Calcium scoring

- EBCT has been around for over 25 years
- EBCT is (only!) good for calcium scoring
- There are large amounts of data on coronary calcium
- Calcium scoring can be performed with MDCT
Good news!

- Calcification of the coronary arteries is a specific marker of atherosclerosis.
Calcium = Atheroma

Coronary Calcium by EBT and Atherosclerotic Plaque by Histopathology

n = 38
r = 0.90
p < .001
Mixed News

- There is a close relationship between coronary calcium and coronary disease but ACS can happen across the entire spectrum of calcium scores.

Coronary Calcification by EBT and Future Coronary Events

The Real Good News

“With a calcium score=0 you have a 0.4% risk of ACS over the next 5 years.”
Why I do not stop CCTA with a Calcium Score=0
30 yo wm, asymptomatic. Three male family members have had MI before the age of 55.
Proximal LAD “Widow maker” atheromatous plaques
Bad News!

- While calcium indicates coronary atheroma it is not necessarily related to stenotic disease.
- There is little relationship between the location of stenotic disease and calcification (no big deal).
- There is little correlation between the site of calcium and vulnerable plaque.
- *Calcium is merely the gravestone of previous episodes of coronary inflammation*
Bad News

- Coronary calcium is very common!
Calcium alone is the tip of the iceberg and you are the Titanic.
ACCF/AHA consensus document JACC Jan 2007

- May be useful in intermediate CHD risk patients in reclassification to high/low risk
- May be useful in helping rule out obstructive coronary disease in atypical chest pain (no calcium has 0.4% risk of MI)
Accuracy of 64-Slice Computed Tomography to Classify and Quantify Plaque Volumes in the Proximal Coronary System

A Comparative Study Using Intravascular Ultrasound

Alexander W. Leber, MD,*§ Alexander Becker, MD,* Andreas Knez, MD,* Franz von Ziegler, MD,* Marc Siroli, MD,§ Konstantin Nikolaou, MD,† Bernd Ohnesorge, PhD,‡ Zahi A. Fayad, PhD,§ Christoph R. Becker, MD,† Maximilian Reiser, MD,† Gerhard Steinbeck, MD,* Peter Boekstegers, MD*

Munich and Forchheim, Germany; and New York, New York

JACC 2006

3. Noncalcified section with an embedded lipid core indicated by echolucency on intravascular ultrasound (IVUS) and hypodensity on 64-slice computed tomography (CT).
DIAGNOSTIC SENSITIVITY

NON-INVASIVE MODALITIES
- STRESS ECG
- STRESS ECHO
- STRESS NUC MED
- PET SCANNING
- MULTI DETECTOR COMPUTED TOMOGRAPHY

INVASIVE MODALITIES
- INTRAVASCULAR ULTRASOUND
- CORONARY ANGIOGRAPHY

0% 10% 45% 60% 70% 90%
So is it worth us finding “early” disease? Can we do anything about it?
Statin effect

- REVERSAL Trial
- 34 centers, 18 month FU, 654 pts
- Assessment of atheroma with IVUS
- Aggressive statin therapy halted disease progression whereas moderate therapy was associated with significant disease progression

Am J Cardiol 2005 Sept 61-68
Effects of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis.

The ASTEROID Trial.

The ASTEROID Trial

- N=349
- All patients received rosuvastatin 40mg/day.
- After 24 months patient serial IVUS comparison
- Mean LDL decrease from 130.4 to 60.8 mg/dl.
- Mean HDL increase from 43.1 to 49.0 mg/dl.
The ASTEROID Trial

Conclusion

High intensity statin therapy resulted in significant regression of atherosclerosis as specified by IVUS.
Effect of Rosuvastatin Therapy on Coronary Artery Stenosis Assessed by Quantitative Coronary Angiography

Rosuvastatin/Serial QCA

- N=507
- Blinded QCA analysis of % diameter stenosis and minimum lumen diameter for up to 10 segments of coronary arteries and major branches with >25% diameter stenosis at baseline.
Rosuvastatin/QCA Results

- Decreased mean LDL by 53.3% and increased mean HDL by 13.8%.
- Mean decrease in diameter stenosis by 37.3% (P<0.001)
- Minimum lumen diameter increased from 1.65mm to 1.67mm (P<0.001)
CCTA Study of Plaque Progression

- Fluvastatin Reduces Coronary Plaque and Increases Lumen Volume: Assessment by MDCT.
- Sato, et. al.- ACC, 2006
- MDCT performed on 16, 32 and 64 MDCT in 12 patients with CAD.
Sato et.al. Fluvastatin and MDCT Progression

- Plaque volume and lumen volume was measured before and after 12 month Rx with Fluvastatin 20mg qd.

- Fluvastatin significantly reduced plaque volume (104.3 +/- 47.8 to 91.2 +/- 36.1 mm³, p=0.045)

- And increased Lumen Volume (97.7 +/- 45.9 to 108.3 +/- 47.0 mm³, p=0.010)
There was no significant change in the lipid profile.
- Total chol 202 to 197.
- LDL 119 to 119.
- HDL 50 to 49.
- TG 168 to 147.
Fibro-atheromatous Plaque

- Calcium
- Contrast
- Fibrosis
- Atheroma
The Cholesterol Test of the Future
53 y.o. wm with positive family history. High cholesterol =190 on Lipitor. Asymptomatic.
ULCERATED PROX. LAD PLAQUE
ULCERATED PROX. LAD PLAQUE
4/30/02
- Total chol. = 190
- Lipitor 10 mg.
- Asymptomatic

6/09/03
- Total chol. = 165
- Lipitor 40mg.
- Asymptomatic
Follow up 14 months later...
Ulcerated Plaque LAD

- Assess plaque size, plaque area, HU at relevant plaque components and degree of stenosis.
4/30/02

- Plaque = 13.6mm long
- Long area = 19.8sq.mm
- Tr. Area = 5.0sq.mm.
- Prox. Fornix = 79 HU
- Dist. Fornix = 73 HU
- Prox. Crater = 221 HU
- Dist. Crater = 403 HU

6/09/03

- Plaque = 13.2mm long
- Long area = 13.7sq.mm
- Tr. Area = 4.5sq.mm
- Prox. Fornix = 91 HU
- Dist. Fornix = 87 HU
- Prox. Crater = 218 HU
- Dist. Crater = 413 HU
Same patient develops “angina like” chest pain and gets his third CCTA on 6/26/04.
Ulcerated Plaque LAD
Plaque length = 13.6, 13.2, 13.2 mm
Long. Area = 19.8, 13.7, 10.8 sq. mm.
Tr. Area = 5.0, 4.5, 5.4 sq. mm.
Prox. Fornix = 79, 91, 98 HU
Dist. Fornix = 73, 87, 99 HU
Prox. Crater = 221, 218, 606 HU
Dist. Crater = 403, 413, 578 HU
Coronary Artery Disease is a Reversible Disease!
Save the Lives of those too Young to have CAD.
27 yo wm with chest pain at rest radiating to the left arm, dyspnea at rest. Risk factors-
hypercholesterolemia, FHx, smoking and HTN.
Diffuse LAD plaque without stenosis
Mild plaque in the RCA and LCX
His 30 yo brother....+FHx, ex-smoker, asymptomatic.
Normal CCTA
44 yo white female with chest pain and total cholesterol = 350.
Normal RCA and PDA
Normal LAD and LCX
39 yo wm with chest pain. Stress test normal. +Fhx, hypercholesterolemia and HTN.
High grade LAD stenosis
High grade LAD stenosis. Normal LCX and RCA.
45 yo wf with chest pain. +FHx, ex-smoker. SPECT stress negative 5 months prior. Pain persists.
50-70% LAD stenosis

Curved phase 75%
Ex: 1946
St: 50/4 w.c.
First Diagonal Anglet: -180,0

DEFIN 4.8 cm
STD Ph: 78% (No Filt.)
505/B

2.9 mm (3D)
2.9 mm (3D)
1.3 mm (3D)

kv 120
ma 447
Rot 0.35s/CH 7.2mm/rot
0.6mm 0.18/1/0.6mm
Tilt: 0.0
01:38:40 PM
W = 1200 L = 200
Normal RCA, Plaque LCX
For the asymptomatic?

- **Low risk CAD**
  Neither

- **Moderate risk CAD**
  CCTA- the stress test negative, CCTA positive patient. Value of statins in this population. Prior to CCTA would you have ordered a stress test here?

- **High risk CAD**
  CCTA. Very often these patients will have a negative CCTA and at the very least may be encouraged to maintain medical management.
38 yo wm, HTN, Hypercholesterolemia, +FHX. Asymptomatic, high performance athlete.
High grade tandem RCA stenoses, LAD plaque, normal LCX.
Tandem RCA Stenoses
55 year old male, asymptomatic, with no family history. Serum cholesterol 205. Runs 3.5 miles per day.
41 yo wm with erectile dysfunction. No risk factors for CAD.
Single Vessel LAD Disease
Is erectile dysfunction the first sign of CAD in males <50 yo?

Is the treatment for ED statin therapy (regardless of cholesterol level) rather than a viagra bandaid?
52 yo, wm asymptomatic.
Hypercholesterolemia.
Left Main Equivalent
Left Main Equivalent
39 yo, wm asymptomatic, helicopter pilot. +FHx, mild hypercholesterolemia.
>70% Stenosis mid-RCA
Normal LCX and LAD
Who is getting statins?
Patients without Hx of CAD (n=1102)

Indications: chest pain with or without risk factors, asymptomatic patients with risk factors (low to intermediate probability of CAD, +FHx.)

- Normal: 27%
- Mild: 47%
- Moderate: 51%
- Severe: 56%
Patients with a Hx of CAD (n=156)

Hx= CABG, stents, angioplasty, MI, “heart artery blockage.”
Non-obstructive Coronary Plaque is a Predictor of all cause Mortality

- N=5018
- Excluded patients with a significant stenosis
- 50.6% had no plaque
- 49.4% had nonobstructing plaque = 3.39x increased risk of all cause mortality.
- Increased risk of 10% mortality over a 10 year period in patients with NO DM, HCO or HTN!

Min J, et. Al., Cornell University
“Coronary CTA Tops Other tests for Long Term Prognosis”

Haamitsky M, et.al. Munich, Germany

- N=1916. Patient had both CCTA and CAC.
- Excluded vessels <1.5mm.
- End point=MACE >90 days after CCTA.
- 36 late events.
- ROC-CCTA=.88, CAC=.75, FRE=.70
CCTA

- Has the potential to demonstrate disease before other non invasive tests
- May be able to allow targeting of therapy for non stenotic soft plaque
- This could reduce sudden death & MI from coronary disease.
How reliable is CCTA at detecting soft plaque?
Atheromatous Plaque
CCTA v. IVUS

- 58 vessels
- 78% sensitive for hypoechoic plaque (HU 49 +/-22)
- 78% sensitive for hyperechoic plaque (HU 91 +/- 22)
- 95% sensitive for calcified plaque (HU 391 +/- 156)
CCTA v. IVUS

- 83 coronary segments
- Any plaque = 78% sens, 87% spec.
- Ca++ plaque = 94% sens, 94% spec.
- NonCa++ plaque = 78% sens, 87% spec.
- But....
CCTA v. IVUS

- If limited to proximal vessels:
  - Any plaque = 92% sens, 88% spec.
  - Ca++ plaque = 95% sens, 91% spec.
  - NonCa++ plaque = 91% sens, 89% spec.
These studies were NOT done on a high mA, EKG dose modulated system.
Does it matter? Does it change patient management?
Yes!!!
Physicians will initiate or maximize statin therapy and perhaps add an ACE Inhibitor in response to the detection of atheromatous plaques!
When you refer to an atheromatous plaque as a “fresh plaque” patients tune in. How long will their motivation last?
Percentage of individuals maintaining statin therapy at 3.6 years according to various levels of baseline CAC

- $0 = 44\%$
- $1-99 = 63\%$
- $100-399 = 75\%$
- $>400 = 90\%$

*Budoff, May 22, 2004*
MDCT screening?

- With new dose reduction techniques this is becoming a feasible option
- We can’t put the whole world on statins!
Coronary CTA as a Screening Tool in an At Risk Occupation Population

Johnson KM, Dowe DA, Min J.
Submitted for Publication
53 yo wm with IDDM, HTN, active smoker and chest pain.
But we can’t put the whole world on statins?
Remodeling Index

>1.4
50yo, wf with chest pain. Normal SPECT. NIDDM, HCO and HTN.
80% LAD stenosis
High Remodeling Index and High Grade Stenosis
But I can’t get a precert?
The William Reilly Coronary CTA Program
William Reilly CCTA Program

- Needs based assessment.
- Applies to those with income <70k.
- Takes number of dependents into account.
- Fill need to submit paystubs, etc., to Susan Christopher, Administrator.
- Final price between $0 and $650.
- Call Susan at 609-653-6708.
Conclusion

- Cardiac CT is the only non-invasive technique that can assess atheromatous burden in the vessel wall and luminal narrowing.
- It has the only noninvasive study that detects the vulnerable plaque. This carries prognostic significance.
- *It has the potential to alter the natural history of CAD*
Thank you.